In humans, 5-HT1D serotonin receptors represent terminal autoreceptors, and there is some evidence that 5-HT1D ligands may be useful in the treatment of migraine. The most widely used 5-HT1D agonist is sumatriptan; however, this agent reportedly displays little selectivity for 5-HT1D versus 5-HT1A receptors. To identify novel serotonergic agents with enhanced 5- HT1D versus 5-HT1A selectivity, we attempted to take advantage of possible differences ...
[Markl, Christian; Clafshenkel, William P.; Attia, Mohamed I.; Sethi, Shalini; Witt-Enderby, Paula A.; Zlotos, Darius P. Archiv der Pharmazie, 2011 , vol. 344, # 10 p. 666 - 674]